University Clinic Rostock
Welcome,         Profile    Billing    Logout  
 2 Trials 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hildebrandt, Guido
NANORAY-312, NCT04892173 / 2021-002163-22: JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

Recruiting
3
500
Europe, Japan, US, RoW
JNJ-90301900 (NBTXR3), Functionalized hafnium oxide nanoparticles, NBTXR3, Cetuximab, Erbitux, Radiation Therapy
Johnson & Johnson Enterprise Innovation Inc., Nanobiotix SA
Locally Advanced Head and Neck Squamous Cell Carcinoma, Aged
06/26
06/27
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated
3
166
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24
NCT04246684: Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients

Active, not recruiting
3
702
Europe
Oxaliplatin, 85 mg/m2, Control arm, 5FU; 2400 mg/m2, 5-FU, control arm, 5FU, 250 mg/m2, Experimental arm: 5-FU, 5FU, 2400 mg/m2, experimental arm, Oxaliplatin 50 mg/m2, Experimental arm, Folinic Acid, 400 mg/m2, Folinic Acid, Radiotherapy control, 5x5 Gy: 25 Gy, Capecitabine, 1000 mg/m2, Capecitabine, Oxaliplatin 85 mg/m2, radiotherapy experimental, 30 x 1,8 Gy: 54 Gy, Capecitabine, 825 mg/m2, Oxaliplatin, 130 mg/m2, Oxaliplatin
Prof. Dr. med. Claus Rödel
Rectal Cancer Stage III
09/23
09/28
FORTplus, NCT05045664: Early Stage Follicular LymphOma and RadioTherapy PLUS Anti-CD20 Antibody

Recruiting
3
100
Europe
Standard, Experimental, Rituximab, Obinutuzumab
Heidelberg University
Early Stage Follicular Lymphoma WHO Grade 1/2 or 3a
12/26
12/29
RADIANCE, NCT04230759 / 2018-003005-25: Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. a Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group

Active, not recruiting
2
180
Europe
Chemotherapy, all brands of 5-fluorouracil (5-FU) are allowed, all brands of Mitomycin C (MMC) are allowed, Radiation, Durvalumab, PD-L1 inhibitor
Goethe University, German Cancer Aid, AstraZeneca
Anal Cancer, Anal Carcinoma, Anal Cancer Stage III, Anal Cancer Stage II
12/26
03/27
PRIMALung, NCT04790253: PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients ( Study)

Recruiting
N/A
600
Europe
Prophylactic cranial irradiation
European Organisation for Research and Treatment of Cancer - EORTC, UNICANCER
Limited Stage Small Cell Lung Cancer, Extensive-stage Small-cell Lung Cancer
04/28
04/28
Dorst, Johannes
IVITOC, NCT04881682: Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Recruiting
2
20
Europe
Immunoadsorption, Immunoglobulins
University of Ulm, Miltenyi Biomedicine GmbH
CIDP
03/26
03/26
NfL-ALS, NCT06201650: Neurofilament Light Chain in Amyotrophic Lateral Sclerosis

Recruiting
N/A
3000
Europe
Neurofilament light chain
Charite University, Berlin, Germany, Boris Canessa ALS Stiftung
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
12/24
12/24
IPET-GBS, NCT04871035: Immunoadsorption Versus Plasma Exchange for Treatment of Guillain-Barré Syndrome (GBS)

Recruiting
N/A
20
Europe
Immunoadsorption, Plasma Exchange
University of Ulm, DiaMed GmbH
GBS
05/25
05/25
KETO-ALS, NCT04820478: Efficacy and Tolerability of Beta Hydroxybutyrate Ester in Patients With Amyotrophic Lateral Sclerosis (ALS)

Recruiting
N/A
76
Europe
Beta Hydroxybutyrate Ester (KetoneAid KE4), Placebo
University of Ulm
Amyotrophic Lateral Sclerosis
10/25
10/25
LIPCAL-ALS II, NCT06280079: Ultra-high-caloric, Fatty Diet in ALS

Recruiting
N/A
392
Europe
Ultra-high-caloric fatty diet, Placebo
University of Ulm
Amyotrophic Lateral Sclerosis
06/27
06/27
Prudlo, Johannes
LIPCAL-ALS II, NCT06280079: Ultra-high-caloric, Fatty Diet in ALS

Recruiting
N/A
392
Europe
Ultra-high-caloric fatty diet, Placebo
University of Ulm
Amyotrophic Lateral Sclerosis
06/27
06/27

Download Options